RT Book, Section
A1 LoVecchio, Frank
A2 Tintinalli, Judith E.
A2 Stapczynski, J. Stephan
A2 Ma, O. John
A2 Yealy, Donald M.
A2 Meckler, Garth D.
A2 Cline, David M.
SR Print(0)
ID 1121499419
T1 Monoamine Oxidase Inhibitors
T2 Tintinalli’s Emergency Medicine: A Comprehensive Study Guide, 8e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071794763
LK accessmedicine.mhmedical.com/content.aspx?aid=1121499419
RD 2024/04/20
AB Monoamine  oxidase  inhibitors  (MAOIs)  were  the  first  class  of  antidepressants,  but  current  use  of  these  agents  is  primarily  limited  to  treating  atypical  and  refractory  cases  of  depression  (Table  179-1).1  Newer  antidepressants  have  a  more  favorable  side  effect  profile,  less  overdose  toxicity,  and  no  dietary  restrictions.  The  declining  popularity  of  oral  MAOIs  for  the  treatment  of  depression  is  partially  offset  by  increasing  use  of  agents  in  this  class  for  the  treatment  of  Parkinson's  disease.2  In  addition,  a  transdermal  method  of  selegiline  administration  is  approved  for  use  in  major  depression  and  appears  to  avoid  some  of  the  worrisome  aspects  associated  with  traditional  oral  therapy.3,4,5